Intelligence Feed event · Equity · 2026-08-27

    Mesoblast Reports FY2026 Revenue of $120.3M on RYONCIL Commercial Launch

    Question

    Mesoblast Reports FY2026 Revenue of $120.3M on RYONCIL Commercial Launch

    Direct answer

    Mesoblast Limited reported full-year 2026 revenue of US$120.3 million, driven primarily by US$115.2 million in net revenue from its commercial launch of RYONCIL. Alongside commercial ramp milestones, the company announced completion of patient dosing in its Phase 3 trial investigating rexlemestrocel-L for chronic low back pain, setting up future regulatory filing windows.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-27
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Mesoblast Reports FY2026 Revenue of $120.3M on RYONCIL Commercial Launch”, revision 1, evidence through 2026-08-27. https://marketontology.com/market-events/2026-08-27/mesoblast-reports-fy2026-revenue-of-120-3m-on-ryoncil-commercial-launch-df0bd0

    EQUITY
    Mesoblast Reports FY2026 Revenue of $120.3M on RYONCIL Commercial Launch
    Mesoblast Limited reported full-year 2026 revenue of US$120.3 million, driven primarily by US$115.2 million in net revenue from its commercial launch of RYONCIL. Alongside commercial ramp milestones, the company announced completion of patient dosing in its Phase 3 trial investigating rexlemestrocel-L for chronic low back pain, setting up future regulatory filing windows.
    MESO
    Impact
    58
    AUG 27
    SIG
    85%
    MESO
    Mesoblast Reports FY2026 Revenue of $120.3M on RYONCIL Commercial Launch
    Mesoblast Limited reported full-year 2026 revenue of US$120.3 million, driven primarily by US$115.2 million in net revenue from its commercial launch of RYONCIL. Alongside commercial ramp milestones, the company announced completion of patient dosing in its Phase 3 trial investigating rexlemestrocel-L for chronic low back pain, setting up future regulatory filing windows.
    → Commercialization revenue from RYONCIL extends Mesoblast cash runway and derisks late-stage rexlemestrocel-L development costs.
    Impact
    Mesoblast Limited reported full-year 2026 revenue of US$120.3 million, driven primarily by US$115.2 million in net revenue from its commercial launch of RYONCIL. Alongside commercial ramp milestones, the company announced completion of patient dosing in its Phase 3 trial investigating rexlemestrocel-L for chronic low back pain, setting up future regulatory filing windows.
    Affected
    MESO
    Transmission
    Commercialization revenue from RYONCIL extends Mesoblast cash runway and derisks late-stage rexlemestrocel-L development costs.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    MESOcommercial product revenue ramp accelerating operational cash flowUp1-5dTotal FY2026 revenue of $120.3M with $115.2M from RYONCIL net sales

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month